By generating gene transcriptional reporter assays, carrying out pharmacological activation or SiRNA knockdown of NRF2, and performing HER2/HER3 functional inhibition and activation strategies, we have identified a direct node of functional integration of the two pathways in our ovarian cancer cell model which converges at NRF2. The gene discussed is ERBB3; the disease is ovarian carcinoma.